Cargando…
Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
BACKGROUND: Controversies exist as to whether the genetic polymorphisms of the enzymes responsible for the metabolism of tamoxifen can predict breast cancer outcome in patients using adjuvant tamoxifen. Direct measurement of concentrations of active tamoxifen metabolites in serum may be a more biolo...
Autores principales: | Helland, Thomas, Henne, Nina, Bifulco, Ersilia, Naume, Bjørn, Borgen, Elin, Kristensen, Vessela N., Kvaløy, Jan T., Lash, Timothy L., Alnæs, Grethe I. G., van Schaik, Ron H., Janssen, Emiel A. M., Hustad, Steinar, Lien, Ernst A., Mellgren, Gunnar, Søiland, Håvard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706168/ https://www.ncbi.nlm.nih.gov/pubmed/29183390 http://dx.doi.org/10.1186/s13058-017-0916-4 |
Ejemplares similares
-
Low Z‐4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen
por: Helland, Thomas, et al.
Publicado: (2020) -
First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: a case study
por: Peccatori, Fedro Alessandro, et al.
Publicado: (2020) -
Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial
por: DeCensi, Andrea, et al.
Publicado: (2021) -
Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer
por: Helland, Thomas, et al.
Publicado: (2021) -
Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment
por: Lien, Ernst A., et al.
Publicado: (2013)